Sugi Predict

Sugi Predict / Compounds / SCHEMBL2761692

SCHEMBL2761692

SCHEMBL2761692

C[C@H](NC(=O)c1c(O)c2c(OCc3ccc(F)cc3)cccc2oc1=O)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 4/20 0.43
▸ BRD4 O60885 1/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ ABCB1 P08183 1/20 0.41
▸ EDNRA P25101 1/20 0.41
▸ PDE5A O76074 1/20 0.41
▸ MRGPRX4 Q96LA9 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ BCHE P06276 1/20 0.39
▸ ACHE P22303 1/20 0.39
▸ MAOB P27338 3/20 0.39
▸ MAOA P21397 3/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ SLC16A3 O15427 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2761691 1.00 ABCG2 (0.43) ABCG2BRD4KMT2ARAB9AABCB1
SCHEMBL2761671 0.92 ABCG2 (0.44) ABCG2BRD4ABCB1EDNRAPDE5A
SCHEMBL2761672 0.92 ABCG2 (0.44) ABCG2BRD4ABCB1EDNRAPDE5A
SCHEMBL2761670 0.83 LMNA (0.43) ABCG2BRD4KMT2ARAB9AABCB1
SCHEMBL2762251 0.83 BRD4 (0.47) ABCG2BRD4KMT2ARAB9AABCB1
SCHEMBL4030419 0.82 LMNA (0.47) ABCG2BRD4KMT2ARAB9AABCB1
SCHEMBL2761742 0.78 LMNA (0.41) KMT2AMEN1LMNAL3MBTL1ACHE
SCHEMBL2761741 0.78 LMNA (0.41) KMT2AMEN1LMNAL3MBTL1ACHE
SCHEMBL2761687 0.77 EDNRA (0.45) ABCG2ABCB1EDNRAPDE5ABCHE
SCHEMBL2761617 0.76 EDNRA (0.54) ABCG2BRD4RAB9AABCB1EDNRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324405-B2 Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors FIBROGEN, INC. (US) 2012-12-04 — — US claimed
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. 2010-12-30 — — US claimed
WO-2009100250-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. (US) 2009-08-13 — — WO claimed
US-8324405-B2 Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors FIBROGEN, INC. (US) 2012-12-04 — — US disclosed
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. 2010-12-30 — — US disclosed
WO-2009100250-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. (US) 2009-08-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS HIF1AN, HIF1A, EGLN2 ABCG2 722/4885BRD4 2439/4885KMT2A 832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.